EPISODE · Feb 9, 2023 · 20 MIN
Lecanemab, pourquoi il suscite de l'espoir ?
from Vos questions, Nos réponses
Un nouveau traitement développé par le laboratoire Eisai a obtenu sa mise sur le marché américain. Il réduirait de 27% le déclin cognitif chez des personnes touchées par une maladie d’Alzheimer à un stade léger.
Embed this episode
Ready to play
Lecanemab, pourquoi il suscite de l'espoir ?
0:00
20:05
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Vos questions, Nos réponses?
This episode is 20 minutes long.
When was this Vos questions, Nos réponses episode published?
This episode was published on February 9, 2023.
Can I download this Vos questions, Nos réponses episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!